HRSA 340B Prime Vendor Agreement

The HRSA 340B Prime Vendor Agreement, managed by Apexus Inc., extends through September 9, 2009, marking the third option year of a five-year contract that originally took effect on September 10, 2004. Over the first four years, Apexus has significantly enhanced the value delivered to 340B safety-net hospitals and clinics by negotiating substantial discounts on over 2,800 brand and generic drugs, achieving average price reductions of 16 percent below the statutory ceiling. The agreement also includes contracts with a diverse network of 14 national, regional, and specialty drug distributors, improving access to medications, particularly for smaller clinics, with alternative distribution options that reduce costs by an average of 7 percent. In addition to drug discounts, Apexus has expanded its offerings to include negotiated reductions on various healthcare-related products and services such as vaccines, diabetic meters and strips, diagnostic test kits, prescription vials, and outpatient pharmacy technology solutions. This multifaceted approach enhances the affordability and availability of pharmaceuticals and related supplies for 340B participants, reinforcing the program’s commitment to support healthcare providers serving vulnerable populations. The contract is managed with designated points of contact to facilitate communication and oversight, ensuring ongoing performance and value delivery.